结直肠癌已然发展到中晚期怎么办？别慌！中晚期结直肠癌亦可实现临床治愈！
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_gif/laxhFHE1XFcJQzh9fqoqb7dYYXNLqOqV6icjlgOKJJEzNZ7jM2kUgO9ic3jZJUZuL1eTTKk7TgoePCfe467EfbLw/640?wx_fmt=gifwxfrom=5wx_lazy=1&tp=webp&wxfrom=5&wx_lazy=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">中国中晚期结直肠癌<span style="color: black;">病人</span>诊疗<span style="color: black;">状况</span>调查结果指出，约83%的结直肠癌<span style="color: black;">病人</span>确诊时<span style="color: black;">已然</span>发展至中晚期，44%的<span style="color: black;">病人</span><span style="color: black;">出现</span>了肝、肺等部位的转移。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">非常多</span>人认为，中晚期结直肠癌<span style="color: black;">寓意</span>着“<span style="color: black;">没</span>药可医”，但其实<span style="color: black;"><strong style="color: blue;">即使是中晚期结直肠癌，<span style="color: black;">恰当</span>治疗后仍<span style="color: black;">能够</span>实现临床治愈</strong></span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/laxhFHE1XFeMiaQ4qjriaZ4iaRvsv6Q14OeiaUftozNich99hY940vzqdaiaCwLTNuN8eia0hmFeww1GYF0eFP5t0Cd4g/640?wx_fmt=other&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">▲图源：</span><span style="color: black;">创客贴</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">转化治疗+手术为肠癌<span style="color: black;">病人</span>带来治愈可能</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">此前，人们<span style="color: black;">始终</span>以为手术是早中期癌症的治疗手段，一旦<span style="color: black;">发展</span>到中晚期，<span style="color: black;">已然</span>失去了手术根治的机会。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">但近年来，越来越多的<span style="color: black;">科研</span>证实，<span style="color: black;"><strong style="color: blue;">中晚期结直肠癌，<span style="color: black;">乃至</span>是<span style="color: black;">已然</span><span style="color: black;">显现</span>远处转移的结直肠癌，仍然<span style="color: black;">能够</span><span style="color: black;">经过</span>手术实现临床治愈</strong></span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">按照</span>《日本结肠直肠癌协会 (JSCCR) 2019 年结直肠癌治疗指南》中的数据<span style="color: black;">表示</span>，<strong style="color: blue;">III期结直肠癌采用手术切除的效果<span style="color: black;">明显</span>，IIIA期5年<span style="color: black;">存活</span>率高达91.9%，IIIB期5年<span style="color: black;">存活</span>率达到81.8%</strong>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">早在2016年<span style="color: black;">发布</span>的<span style="color: black;">相关</span>“结直肠癌手术的效果和复发率”的综述中的数据<span style="color: black;">表示</span>，<strong style="color: blue;">肝转移病灶完全切除的结直肠癌<span style="color: black;">病人</span>5年<span style="color: black;">存活</span>率高达60%</strong>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/laxhFHE1XFetuzVQgdVicrhk5iaM8ibBqzydqichQ0ncARNTgneXNhv5BcibwvavjibQicSg9ibXOKiacemicfEVhjibjoahA/640?wx_fmt=png&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">▲图源：参考<span style="color: black;">源自</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">除此之外，许多初诊<span style="color: black;">没</span>法手术的结直肠癌<span style="color: black;">病人</span>，<span style="color: black;">亦</span>仍有机会通过转化治疗遏制肿瘤，<span style="color: black;">得到</span>手术机会。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">转化治疗是一种<span style="color: black;">经过</span>对适合<span style="color: black;">病人</span>进行术前系统或局部治疗，使肿瘤缩小，<span style="color: black;">从而</span>将初始不可切除病灶转化为可手术切除病灶的治疗<span style="color: black;">办法</span>。多项<span style="color: black;">科研</span><span style="color: black;">显示</span>，<span style="color: black;"><strong style="color: blue;"><span style="color: black;">经过</span>采用术前<span style="color: black;">药品</span>治疗<span style="color: black;">能够</span>将初始不可切除的晚期结直肠癌<span style="color: black;">病人</span>转变为可切除，<span style="color: black;">针对</span><span style="color: black;">加强</span><span style="color: black;">病人</span>的手术切除率，<span style="color: black;">加强</span><span style="color: black;">存活</span>期<span style="color: black;">拥有</span><span style="color: black;">要紧</span><span style="color: black;">道理</span></strong></span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2004年发表在《临床肿瘤学杂志（Journal of Clinical Oncology）》的<span style="color: black;">科研</span><span style="color: black;">已然</span>证实，<strong style="color: blue;">FOLFIRI（氟尿嘧啶+伊立替康）、FOLFOX（氟尿嘧啶+奥沙利铂）传统化疗<span style="color: black;">方法</span>能够实现9%-22%的转化率</strong>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2019年<span style="color: black;">发布</span>的一项<span style="color: black;">科研</span><span style="color: black;">评定</span>了Vectibix(panitumumab，帕尼单抗）联合化疗治疗不可切除的RAS野生型结直肠癌肝转移<span style="color: black;">病人</span>的效果，<span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，<strong style="color: blue;">与单独采用化疗相比，Vectibix联合化疗组缓解率<span style="color: black;">明显</span><span style="color: black;">加强</span></strong>（87.3% vs 60.6%），<strong style="color: blue;">且切除率增长近1倍</strong>（33.3% vs12.1%）。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/laxhFHE1XFetuzVQgdVicrhk5iaM8ibBqzyBEkpqgnl2xZ0mQ5LzwfbVjwy0s96MzHC4e0j7C6NP8E1T5xGSK5x4A/640?wx_fmt=png&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">▲图源：参考<span style="color: black;">源自</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">精细</span><span style="color: black;">药品</span>疗法延长晚期肠癌<span style="color: black;">病人</span><span style="color: black;">存活</span>期</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">药品</span>治疗是晚期结直肠癌<span style="color: black;">重点</span>的治疗<span style="color: black;">选取</span>，近年来，<strong style="color: blue;">靶向疗法及免疫疗法等<span style="color: black;">精细</span><span style="color: black;">药品</span>疗法的<span style="color: black;">显现</span><span style="color: black;">明显</span>延长了晚期结直肠癌<span style="color: black;">病人</span>的<span style="color: black;">存活</span>期，为结直肠癌<span style="color: black;">病人</span>带来了更好的预后</strong>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">靶向治疗</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">分子靶向<span style="color: black;">药品</span>治疗是近年新兴的一种治疗手段，因其<span style="color: black;">拥有</span>高度<span style="color: black;">选取</span>性地杀死肿瘤细胞而不杀伤或仅很少<span style="color: black;">损害</span>正常细胞的特点，安全性和耐受性较好、毒副<span style="color: black;">功效</span>相对较小。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">截止到<span style="color: black;">日前</span>，共有7款靶向治疗<span style="color: black;">药品</span><span style="color: black;">得到</span>美国FDA<span style="color: black;">准许</span>可用于结直肠癌的治疗，分别是<span style="color: black;"><strong style="color: blue;">靶向血管形成 (VEGF) 的<span style="color: black;">药品</span>：贝伐单抗、Cyramza、Ziv-aflibercept；靶向EGFR突变的<span style="color: black;">药品</span>：Erbitux、Vectibix；靶向BRAF突变的<span style="color: black;">药品</span>Braftovi以及其他靶向<span style="color: black;">药品</span>Regorafenib</strong></span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">另一</span>，双靶向疗法的<span style="color: black;">显现</span><span style="color: black;">亦</span>有望延长结直肠癌<span style="color: black;">病人</span>的<span style="color: black;">存活</span>期。早在2020年，<span style="color: black;"><strong style="color: blue;">Braftovi与Erbitux的联合用药<span style="color: black;">方法</span></strong></span>已被<span style="color: black;">准许</span>用于携带BRAF V600E突变的转移性结直肠癌（mCRC）成人<span style="color: black;">病人</span>的治疗。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">免疫治疗</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂可阻断免疫<span style="color: black;">控制</span>通路，恢复<span style="color: black;">身体</span>免疫细胞对癌细胞的杀伤力，阻断肿瘤抗原性逃逸，<span style="color: black;">因此呢</span>，以PD-1/PD-L1单抗为<span style="color: black;">表率</span>的免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂在多种肿瘤治疗中都大有用武之地。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">日前</span>已被<span style="color: black;">准许</span>用于结直肠癌的免疫<span style="color: black;">药品</span><span style="color: black;">包含</span><span style="color: black;"><strong style="color: blue;">抗PD-1疗法Opdivo（nivolumab，纳武单抗）、Keytruda（pembrolizumab）、抗CTLA-4疗法Yervoy（ipilimumab，易普利姆玛）</strong></span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">另一</span>，双免疫疗法的<span style="color: black;">显现</span><span style="color: black;">亦</span>有望延长结直肠癌<span style="color: black;">病人</span>的<span style="color: black;">存活</span>期。2018年，<span style="color: black;"><strong style="color: blue;">抗PD-1疗法Opdivo联合抗CTLA-4疗法Yervoy的双免疫疗法</strong></span>率先<span style="color: black;">获准</span>，用于治疗既往接受氟尿嘧啶（fluoropyrimidine）、奥沙利铂（oxaliplatin）、伊立替康（irinotecan）治疗后病情<span style="color: black;">发展</span>、dMMR或MSI-H转移性结直肠癌（mCRC）成人及12岁及以上儿科<span style="color: black;">病人</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">不仅如此，在2022年美国临床肿瘤学会（ASCO）年会中，一项<span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，<span style="color: black;"><strong style="color: blue;">免疫治疗<span style="color: black;">能够</span><span style="color: black;">做为</span>局部晚期直肠癌的根治性疗法，实现100%缓解！</strong></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">科研</span>纳入了12例II期和III期错配修复缺陷直肠腺癌<span style="color: black;">病人</span>，<strong style="color: blue;">在仅采用Dostarlimab治疗后进行了不<span style="color: black;">小于</span>6个月的随访（6-25个月），结果<span style="color: black;">表示</span>，<span style="color: black;">100%的<span style="color: black;">病人</span>均达到临床完全缓解</span></strong>，在MRI、FDG-PET、电子可视化内镜、直肠指检或活检均<span style="color: black;">没</span>肿瘤迹象，且在随访<span style="color: black;">时期</span>并未<span style="color: black;">显现</span>任何复发迹象。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/laxhFHE1XFetuzVQgdVicrhk5iaM8ibBqzyTAKy8jz1z25E4PXjCEw9Qujnh1UibcJslS4L4nT2y4yE99U6vOpgiccg/640?wx_fmt=png&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">▲图源：2022 ASCO年会</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">总而言之，随着医疗技术的<span style="color: black;">持续</span>进步，中晚期结直肠癌的<span style="color: black;">存活</span>率<span style="color: black;">亦</span>在<span style="color: black;">逐步</span><span style="color: black;">提高</span>，越来越多的中晚期结直肠癌<span style="color: black;">病人</span><span style="color: black;">能够</span>在<span style="color: black;">恰当</span>治疗后<span style="color: black;">得到</span>良好的预后。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">然则</span>，<strong style="color: blue;">中晚期结直肠癌的治疗<span style="color: black;">触及</span>到各个环节，<span style="color: black;">包含</span>手术，放疗科的全程参与，后续的免疫治疗，以及治疗过程中的全病程管理等，<span style="color: black;">仅有</span>多学科相互协作，<span style="color: black;">才可</span>让结直肠癌<span style="color: black;">病人</span><span style="color: black;">得到</span>更好的预后</strong>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，</span><span style="color: black;"><strong style="color: blue;">日本以结直肠癌5年<span style="color: black;">存活</span>率72.5%、10年<span style="color: black;">存活</span>率69.7%的超高数据远超其他国家</strong></span><span style="color: black;">(中国5年<span style="color: black;">存活</span>率为56.9%)，<span style="color: black;">作为</span>结直肠癌<span style="color: black;">病人</span>出国<span style="color: black;">看病</span>的优选。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">厚朴方舟<span style="color: black;">做为</span>国内知名海外医疗服务<span style="color: black;">公司</span>，与世界多家权威结直肠癌治疗医院有着深入的合作关系，<span style="color: black;">能够</span><span style="color: black;">供给</span>远程会诊及<span style="color: black;">看病</span>服务，为<span style="color: black;">没</span>数结直肠癌<span style="color: black;">病人</span>带来治愈<span style="color: black;">期盼</span>：</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">66岁的吴先生确诊直肠癌肝转移，经过三次化疗后<span style="color: black;">没</span>法确定<span style="color: black;">是不是</span><span style="color: black;">能够</span>手术，<span style="color: black;">经过</span>厚朴方舟联系到<strong style="color: blue;">日本肠癌专家福永正气教授</strong>，教授指出，<span style="color: black;">已然</span>符合手术适应症，<span style="color: black;">没</span>需再次化疗<span style="color: black;">就可</span>手术。<span style="color: black;">举荐</span>阅读：<a style="color: black;">【厚朴案例】肠癌肝转移<span style="color: black;">亦</span>能手术根除？日本专家福永正气为<span style="color: black;">病人</span>指点迷津</a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">确诊乙状结肠腺癌伴双肺转移的吴先生经过2位日本顺天堂大学<span style="color: black;">附庸</span>顺天堂医院的权威专家<span style="color: black;">一起</span>诊治后<strong style="color: blue;"><span style="color: black;">（一位是微创外科<span style="color: black;">专家</span>，<span style="color: black;">善于</span>消化道肿瘤微创手术和综合治疗的福永哲教授，另一位是<span style="color: black;">呼气</span>外科<span style="color: black;">专家</span>，世界达芬奇<span style="color: black;">设备</span>人设备<span style="color: black;">开发</span>团队核心成员铃木健司教授）</span></strong>，经过三次微创手术已完全切除肿瘤。<span style="color: black;">举荐</span>阅读：<a style="color: black;">【厚朴案例】结肠癌双肺转移，两位国宝级<span style="color: black;">大夫</span>三次微创手术系数清除！</a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">薛先生（化名）是一名确诊为直肠癌肝转移的<span style="color: black;">病人</span>，虽然经历了多次治疗，但肿瘤仍然<span style="color: black;">显现</span>了复发。经过远程会诊后，<span style="color: black;"><strong style="color: blue;">日本权威专家川崎诚治教授</strong></span>指出，<strong style="color: blue;">即使是多次复发的肠癌肝转移<span style="color: black;">病人</span>，仍有57%的临床治愈可能</strong>。<span style="color: black;">举荐</span>阅读：<a style="color: black;">【厚朴案例】多次治疗，数次复发，肠癌肝转移<span style="color: black;">病人</span>面临<span style="color: black;">存活</span><span style="color: black;">危险</span>！日本专家点亮治愈<span style="color: black;">期盼</span></a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">确诊直肠癌的李琳（化名）在<span style="color: black;">检测</span>中<span style="color: black;">发掘</span>肝内多发转移、右肺上叶有小结节，不排除转移。国内<span style="color: black;">大夫</span><span style="color: black;">意见</span>先进行化疗，<span style="color: black;">倘若</span>化疗效果好后续<span style="color: black;">能够</span>采取手术根除肿瘤。但化疗结束后，<span style="color: black;">大夫</span>告诉她并<span style="color: black;">无</span>达到手术的适应症<span style="color: black;">需求</span>，还<span style="color: black;">必须</span>进行下一次的化疗。为了寻求更好的诊断，李琳找到<strong style="color: blue;">厚朴方舟<span style="color: black;">起步</span>大肠外科和肝胆胰外科专家的联合多学科会诊</strong>。会诊中，专家指出，<span style="color: black;">已然</span><span style="color: black;">能够</span>手术！<span style="color: black;">举荐</span>阅读：<a style="color: black;">【厚朴案例】推翻诊断！多学科远程会诊破直肠癌合并肝、肺转移<span style="color: black;">病人</span>“疑案”</a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">倘若</span><span style="color: black;">期盼</span><span style="color: black;">认识</span><span style="color: black;">更加多</span>结直肠癌治疗内容，或有意向寻求结直肠癌专家诊治的，<span style="color: black;">能够</span>拨打热线<span style="color: black;"><strong style="color: blue;">400-081-6600</strong></span>或添加<span style="color: black;">微X</span><span style="color: black;"><strong style="color: blue;">DrHopeNoah</strong></span>联系<span style="color: black;">咱们</span>。</p><img src="https://mmbiz.qpic.cn/mmbiz_gif/laxhFHE1XFfxyOQHUyRdsV58BrhCCQmSggk1L21a27Zr4CFTjzEUs1gI4DrxKUWyK1w5rfEtT0SII7PYRhSBkA/640?wx_fmt=gif&from=appmsg&wxfrom=5&wx_lazy=1&tp=webp" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">健康所系，性命相托，厚朴方舟愿用<span style="color: black;">优秀</span>的医疗服务，<span style="color: black;">作为</span>您心中的诺亚方舟。厚朴方舟2012年进入海外医疗<span style="color: black;">行业</span>，<span style="color: black;">日前</span>已<span style="color: black;">作为</span>国内知名海外医疗服务<span style="color: black;">公司</span>，<strong style="color: blue;"><span style="color: black;">持有</span>来自<span style="color: black;">全世界</span>多个国家并经过严格筛选的权威<span style="color: black;">大夫</span>团队，<span style="color: black;">长时间</span>密切合作的医院多达百余家</strong>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/laxhFHE1XFdNnJ8YicOm5y5ibjwBvdtqia7jtPTMACe0syc7GQbfoXibP5jicKIBL7Rb8DXkfxNVOrWpvDFeDz49SZQ/640?wx_fmt=other&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">数年</span>来，肩负<strong style="color: blue;"><span style="color: black;">“只为更好医疗”</span></strong>的使命，厚朴方舟利用<span style="color: black;">优秀</span>的国际医疗资源，<strong style="color: blue;"><span style="color: black;">按照</span><span style="color: black;">病人</span>病情快速匹配适合的<span style="color: black;">大夫</span>医院，规划更<span style="color: black;">恰当</span>的<span style="color: black;">看病</span><span style="color: black;">方法</span>，快速预约权威专家远程会诊咨询、<span style="color: black;">短期</span>内抵达海外<span style="color: black;">看病</span></strong>等，为数以万计的<span style="color: black;">病人</span>和家庭<span style="color: black;">供给</span>了<strong style="color: blue;"><span style="color: black;">“更好、更快、更省”</span></strong>的<span style="color: black;">优秀</span>海外医疗服务！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">往期精彩回顾</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;">手术切除<span style="color: black;">为何</span>是肾癌治疗的金标准？肾癌术后10年总<span style="color: black;">存活</span>率高达96%！</a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;">子宫内膜癌5年<span style="color: black;">存活</span>率81%！美国治疗子宫内膜癌的<span style="color: black;">优良</span>在于...</a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;">质子治疗与手术、化疗完美<span style="color: black;">协同</span>，<span style="color: black;">作为</span>癌症治疗的<span style="color: black;">要紧</span><span style="color: black;">选取</span>！</a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">版权声明：本文为厚朴方舟原创内容，版权归厚朴方舟所有，欢迎转发<span style="color: black;">伴侣</span>圈，任何公众号或其他<span style="color: black;">媒介</span>转载<span style="color: black;">必要</span>注明<span style="color: black;">源自</span>于【厚朴方舟】（ID：hope-noah）<span style="color: black;">或</span>后台联系<span style="color: black;">博主</span>开白名单。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">参考<span style="color: black;">源自</span>：</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020 Jan;25(1):1-42. doi: 10.1007/s10147-019-01485-z. Epub 2019 Jun 15. PMID: 31203527; PMCID: PMC6946738.</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Recurrence after hepatic resection in colorectal cancer liver metastasis -Review article-</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564049/</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15;22(2):229-37. doi: 10.1200/JCO.2004.05.113. Epub 2003 Dec 2. PMID: 14657227.</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Ricke J, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Geissler M. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol. 2019 Dec 10;37(35):3401-3411. doi: 10.1200/JCO.19.01340. Epub 2019 Oct 14. PMID: 31609637.</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Colorectal Cancer Treatment Program</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">https://www.massgeneral.org/cancer-center/treatments-and-services/gastrointestinal-cancers/colorectal-cancer</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2022年美国临床肿瘤学会（ASCO）年会</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">免责声明：本公众号内容仅作交流参考，不<span style="color: black;">做为</span>诊断及医疗依据，专业医学问题请咨询专业人士或专业医疗<span style="color: black;">公司</span>。</p>
楼主的文章深得我心，表示由衷的感谢！ 你的见解独到，让我受益匪浅，非常感谢。 百度seo优化论坛 http://www.fok120.com/ 认真阅读了楼主的帖子，非常有益。 谢谢、感谢、感恩、辛苦了、有你真好等。
页:
[1]